ABSTRACTS – ORAL PRESENTATIONS - AMCA, spol. s r.o.

Acknowledgements
This work was supported by IGA NT/11414-5, IGA NT/1327
References
Costimulatory molecules and cytokine production by T lymphocytes in common variable
immunodeficiency disease. Pons J, Ferrer JM, Martínez-Pomar N, Iglesias-Alzueta J,
Matamoros N. Scand J Immunol. 2006 May;63(5):383-9.
B-cell-T-cell activation and interaction in common variable immunodeficiency. Rezaei
N, Wing JB, Aghamohammadi A, Carlring J, Lees A, Asgarian-Omran H, Pourpak Z,
Sarrafnejad A, Kardar GA, Shahrestani T, Masoumi F, Zare A, Saghafi S, Sarrafzadeh S,
Foster RA, Heath AW, Read RC. Hum Immunol. 2010 Apr;71(4):355-62.
P67. ASSESSMENT OF KINETICS OF LEUKEMIC BLAST ELIMINATION DURING THE
INDUCTION TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA USING MULTICOLOR
FLOW CYTOMETRY
M. Twardoch 1 , A. Sonsala 1 , J. Bulsa 1 , I. Malinowska 2 , U. Małek 3 , J. Trelińska 4 ,
E. Niedzielska 5 , K. Derwich 6 , W. Badowska 7 , M. Niedźwiecki 8 , G. Sobol 9 ,
K. Muszyńska-Rosłan 10 , M. Wysocki 11 , G. Karolczyk 12 , M. Wieczorek 13 ,
T. Urasiński 14 , J. Kowalczyk 3 , B. Mazur 15 , T. Szczepański 1 , Ł. Sędek 1
1
Department of Pediatric Hematology and Oncology, Medical University of Silesia,
Zabrze, Poland; hajdix@gmail.com
University Departments and Hospitals of Polish Pediatric Leukemia and Lymphoma
Study Group:
2
Warszawa, 3 Lublin, 4 Łódź, 5 Wrocław, 6 Poznań, 7 Olsztyn, 8 Gdańsk, 9 Katowice,
10
Białystok, 11 Bydgoszcz, 12 Kielce, 13 Chorzów, 14 Szczecin;
15
Department of Microbiology and Immunology Medical University of Silesia, Zabrze,
Poland
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. ALL
comprises about 80% of childhood leukemias in Poland (Kowalczyk, 2011). The level of
minimal residual disease (MRD) is generally considered as a major prognostic factor for
monitoring patients with ALL during the treatment (Szczepański, 2007). Evaluation of
the MRD level is used for risk group stratification and thereby allows applying effective
treatment protocols in these patients (Conter et al., 2010; Schrappe et al., 2011).
The study purpose was to compare the levels of residual disease on days 15 and 33
of treatment in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and T-lineage
acute lymphoblastic leukemia (T-ALL).
We studied 439 patients with ALL (384 with BCP-ALL and 55 with T-ALL), treated in
the centers of the Polish Pediatric Leukemia/Lymphoma Study Group. Bone marrow
samples were stained at diagnosis of leukemia with 8-color monoclonal antibody panels
developed by the EuroFlow consortium (van Dongen et al., 2012). Precise leukemia
associated immunophenotype was determined for each patient which facilitated their
follow up at days 15 and 33 of induction treatment. The samples were acquired with the
168 Analytical Cytometry VII